ATC level 3
L01FCancer medicines (antineoplastics), subgroup L01F
- Molecules
- 54
- Subgroups
- 9
ATC L01F (Cancer medicines (antineoplastics), subgroup L01F) is a level 3 group in the anatomical therapeutic chemical classification. The catalogue lists 54 molecules in it, each with brands, manufacturers and supply from India.
ATC codes are used as identifiers. Class names are written by MedsAcross and are not the WHO Collaborating Centre's text.
Subgroups
- L01FACancer medicines (antineoplastics), subgroup L01F, subgroup L01FA3
- L01FBCancer medicines (antineoplastics), subgroup L01F, subgroup L01FB1
- L01FCCancer medicines (antineoplastics), subgroup L01F, subgroup L01FC1
- L01FDCancer medicines (antineoplastics), subgroup L01F, subgroup L01FD5
- L01FECancer medicines (antineoplastics), subgroup L01F, subgroup L01FE1
- L01FFCancer medicines (antineoplastics), subgroup L01F, subgroup L01FF11
- L01FGCancer medicines (antineoplastics), subgroup L01F, subgroup L01FG2
- L01FXCancer medicines (antineoplastics), subgroup L01F, subgroup L01FX31
- L01FYCancer medicines (antineoplastics), subgroup L01F, subgroup L01FY1
Molecules
Molecules with an ATC code under L01F.
- AmivantamabBiologic1 presentation1 brandL01FX18
- AtezolizumabOrphanAntibodies2 presentations2 brandsL01FF05
- AvelumabOrphanAntibodies1 presentation2 brandsL01FF04
- Belantamab mafodotinOrphan1 presentation2 brandsL01FX15
- BevacizumabOrphanVascular Endothelial Growth Factor Inhibitor13 presentations17 brandsL01FG01
- BlinatumomabOrphan1 presentation2 brandsL01FX07
- Brentuximab vedotinOrphanCD30-directed Immunoconjugate1 presentation2 brandsL01FX05
- Catumaxomab1 brandL01FX03
- CetuximabOrphanEpidermal Growth Factor Receptor Antagonist2 presentations2 brandsL01FE01
- DaratumumabOrphanAntibodies3 presentations2 brandsL01FC01
- Datopotamab deruxtecanBiologic1 presentation2 brandsL01FX35
- DinutuximabOrphanGlycolipid Disialoganglioside-directed Antibody1 presentation1 brandL01FX06
- Dinutuximab betaOrphan1 brandL01FX06
- DostarlimabBiologicProgrammed Death Receptor-1 Blocking Antibody1 presentation2 brandsL01FF07
- DurvalumabOrphanAntibodies2 presentations2 brandsL01FF03
- ElotuzumabOrphanAntibodies2 presentations2 brandsL01FX08
- Enfortumab vedotinBiologic1 presentation2 brandsL01FX13
- EpcoritamabOrphanBispecific CD20-directed CD3 T Cell Engager2 presentations2 brandsL01FX27
- Gemtuzumab ozogamicinOrphanCD33-directed Immunoconjugate1 presentation2 brandsL01FX02
- GlofitamabBiologicBispecific CD20-directed CD3 T Cell Engager2 presentations2 brandsL01FX28
- Inotuzumab ozogamicinOrphanCD22-directed Immunoconjugate1 presentation2 brandsL01FB01
- IpilimumabOrphanCTLA-4-directed Blocking Antibody2 presentations2 brandsL01FX04
- LinvoseltamabOrphan1 brandL01FX
- Loncastuximab tesirineOrphan1 presentation2 brandsL01FX22
- Mirvetuximab soravtansineOrphan1 presentation2 brandsL01FX26
- MogamulizumabOrphanAntibodies1 presentation2 brandsL01FX09
- MosunetuzumabOrphan4 presentations3 brandsL01FX25
- NarsoplimabOrphan1 presentation1 brandL01FX
- NivolumabOrphanProgrammed Death Receptor-1 Blocking Antibody4 presentations2 brandsL01FF01
- Nivolumab and RelatlimabOrphanLymphocyte Activation Gene-3 Blocker1 presentation2 brandsL01FY02
- ObinutuzumabOrphanCD20-directed Cytolytic Antibody1 presentation2 brandsL01FA03
- OfatumumabOrphanCD20-directed Cytolytic Antibody1 presentation2 brandsL01FA02
- PembrolizumabOrphanProgrammed Death Receptor-1 Blocking Antibody1 presentation1 brandL01FF02
- PertuzumabBiologicHER2/neu Receptor Antagonist1 presentation3 brandsL01FD02
- Polatuzumab vedotinOrphan2 presentations2 brandsL01FX14
- RamucirumabOrphanVascular Endothelial Growth Factor Receptor 2 Antagonist2 presentations2 brandsL01FG02
- RetifanlimabOrphanProgrammed Death Receptor-1 Blocking Antibody1 presentation2 brandsL01FF10
- RituximabOrphanCD20-directed Cytolytic Antibody8 presentations11 brandsL01FA01
- Sacituzumab govitecanBiologic1 presentation2 brandsL01FX06
- Serplulimab1 brandL01FF12
- Sugemalimab1 brandL01FF11
- TafasitamabOrphan1 presentation2 brandsL01FX12
- TalquetamabOrphan2 presentations2 brandsL01FX29
- TarlatamabOrphan1 presentation2 brandsL01FX33
- TeclistamabOrphan2 presentations1 brandL01FX24
- TislelizumabOrphanProgrammed Death Receptor-1 Blocking Antibody2 presentations2 brandsL01FF09
- Tisotumab vedotinBiologic1 presentation2 brandsL01FX23
- ToripalimabOrphanProgrammed Death Receptor-1 Blocking Antibody1 presentation2 brandsL01FF13
- TrastuzumabOrphanHER2/neu Receptor Antagonist14 presentations18 brandsL01FD01
- Trastuzumab deruxtecanBiologic1 presentation2 brandsL01FD04
- Trastuzumab emtansineBiologic1 presentation2 brandsL01FD03
- TremelimumabOrphanCTLA-4-directed Blocking Antibody2 presentations2 brandsL01FX20
- ZanidatamabOrphanBispecific HER2-directed Antibody1 presentation2 brandsL01FD07
- ZolbetuximabOrphanClaudin 18.2-directed Cytolytic Antibody1 presentation2 brandsL01FX31
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Cannot find the medicine you need?
Our sourcing team can find unlisted, unapproved and hard-to-find medicines through licensed channels.